menu

0
  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional
portada Respiratory Disease in the COVID-19 Era (in English)
Type
Physical Book
Publisher
Language
Inglés
Pages
112
Format
Hardcover
Dimensions
24.4 x 17.0 x 1.1 cm
Weight
0.44 kg.
ISBN13
9783036579160
Categories

Respiratory Disease in the COVID-19 Era (in English)

Okamoto, Masaki (Author) · Mdpi AG · Hardcover

Respiratory Disease in the COVID-19 Era (in English) - Okamoto, Masaki

Physical Book

$ 48.81

$ 61.01

You save: $ 12.20

20% discount
  • Condition: New
It will be shipped from our warehouse between Friday, June 21 and Monday, June 24.
You will receive it anywhere in United States between 1 and 3 business days after shipment.

Synopsis "Respiratory Disease in the COVID-19 Era (in English)"

Coronavirus disease 2019 (COVID-19) is a new respiratory disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused a global pandemic. COVID-19 patients often develop acute respiratory distress syndrome (ARDS), which involves acute and lethal respiratory failure. In a meta-analysis, the median incidence of ARDS in COVID-19 patients was found to be 35 (2-79)%, while the mortality rate in COVID-19-associated ARDS patients was found to be 39 (12.5-73.1)% (Hasan, et al. Expert Rev Repoir Med. 2020; 14: 1149). As of 12 December 2021, 270,373,764 cases had been confirmed as COVID-19 and 5,321,321 cases had resulted in death, according to the World Health Organization webpage. Various symptoms such as persistent fatigue, myalgia, and insomnia can persist after recovery from COVID-19; these symptoms are called "long COVID-19". Patients with COVID-19 who survive but develop pulmonary fibrosis may experience persistent dyspnea upon exertion, a decrease in pulmonary function, and/or a radiological abnormal shadow. Antifibrotic drugs including nintedanib and pirfenidone are candidate drugs for the treatment of pulmonary fibrosis due to COVID-19; randomized controlled trials are ongoing.However, there are limited studies about respiratory disease caused by COVID-19. Given the clinical significance of this topic and its impact on clinical practice and public health, Medicina have published a Special Issue entitled "Respiratory Disease in the COVID-19 Era" with the aim of gathering accurate and up-to-date scientific information of this topic.

Customers reviews

More customer reviews
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)
  • 0% (0)

Frequently Asked Questions about the Book

All books in our catalog are Original.
The book is written in English.
The binding of this edition is Hardcover.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews